Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Remodeling01:40

Bone Remodeling

34.4K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
34.4K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Bone Disorders01:29

Bone Disorders

8.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.0K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

3.5K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.5K
Essential Minerals for Bone Health01:31

Essential Minerals for Bone Health

6.3K
The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
6.3K
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

5.1K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between 10-year cardiovascular risk and fracture incidence in postmenopausal women: a prospective analysis from the Women's Health Initiative.

Lancet regional health. Americas·2026
Same author

Goal-directed therapy is not as simple as it seems.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients With Osteoporosis: A Systematic Review and Osteonecrosis of the Jaw Taskforce Consensus Statement.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2025
Same author

Identifying Younger Postmenopausal Women With Osteoporosis Using USPSTF-Recommended Osteoporosis Risk Assessment Tools.

JAMA network open·2025
Same author

What to Do When Denosumab Is Stopped?

JAMA network open·2024
Same author

New Challenges: Use and Interpretation of Radius Bone Mineral Density.

The Journal of clinical endocrinology and metabolism·2024

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K

Denosumab in osteoporosis.

Dima L Diab1, Nelson B Watts

  • 1University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati VA Medical Center, Division of Endocrinology/Metabolism, Department of Internal Medicine , 260 Stetson St, Suite 4200, Cincinnati, OH 45219 , USA +1 513 558 4444 ; +1 513 558 8581 ; diabd@ucmail.uc.edu.

Expert Opinion on Drug Safety
|December 3, 2013
PubMed
Summary

Denosumab effectively treats osteoporosis by improving bone density and reducing fractures in various patient groups. While generally safe, potential side effects require careful consideration.

More Related Videos

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

7.4K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

8.8K

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K
Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

7.4K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

8.8K

Area of Science:

  • Pharmacology
  • Bone Biology
  • Clinical Medicine

Background:

  • Denosumab is a fully human monoclonal antibody targeting the receptor activator of nuclear factor kappa-B ligand (RANKL).
  • It functions as an antiresorptive agent, inhibiting osteoclast formation and activity.

Purpose of the Study:

  • To review denosumab's efficacy and safety for osteoporosis treatment.
  • To evaluate its role in managing bone loss in specific patient populations.

Main Methods:

  • Drug evaluation of denosumab for osteoporosis.
  • Analysis of clinical trial data on bone mineral density (BMD) and fracture incidence.
  • Review of safety profiles and adverse events.

Main Results:

  • Denosumab improves BMD and reduces vertebral, hip, and nonvertebral fractures in postmenopausal women.
  • It prevents bone loss and reduces vertebral fracture risk in men on androgen deprivation therapy.
  • Safety concerns include infections, hypocalcemia, and osteonecrosis of the jaw.

Conclusions:

  • Denosumab can be an initial therapy option for high-risk osteoporosis patients, including older adults and those with renal impairment.
  • It may be suitable for patients intolerant or unresponsive to other treatments.
  • Further research is needed on long-term use, discontinuation, and comprehensive safety data.